+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 1
Age: 13Years +
All Genders
ID00000779

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With > 500 CD4 Cellsmm3

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04

130

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

PRIMARY: To compare the immunogenicity and safety of each of several HIV-1 derived immunogens versus control in HIV-infected individuals with CD4 counts greater than or equal to 500 cells/mm3. SECONDARY: To determine whether significant advantages to any one vaccine exist. Before large clinical trials of anti-HIV vaccines are undertaken, it is important to determine whether there are significant advantages to any one of the vaccines currently offered for such studies.

CONDITIONS

Brief Title

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here